-
2 months ago | 
bioprocessintl.com | Josh Abbott |Shreeyashi Ojha
In a 53-47 vote that fell entirely across party lines, Robert F. Kennedy Jr. was confirmed by the US Senate to lead the Department of Health and Human Services as secretary. Ultimately, the few Republican senators such as Bill Cassidy (R-LA), who had expressed skepticism in President Donald Trump’s pick, fell in line, making official the result that analysts expected.
-
Jan 15, 2025 | 
bioprocessintl.com | Josh Abbott
Samarth Kulkarni, CEO of CRISPR Therapeutics, spoke at the JP Morgan Healthcare Conference about his firm’s development of allogeneic therapies and their manufacturing and cost advantages compared with autologous therapies.
-
Jan 10, 2025 | 
bioprocessintl.com | Josh Abbott
Contract development and manufacturing organization (CDMO) Samsung Biologics extended its partnership with Korea-based biopharmaceutical development firm LigaChem Biosciences to provide antibody-drug conjugate (ADC) services. The extension stems from an agreement first signed by the two companies in February 2024. A spokesperson for Samsung Biologics told BioProcess Insider that the companies will collaborate on three projects for the development of ADC therapies.
-
Jan 8, 2025 | 
bioprocessintl.com | Josh Abbott
Under terms of the deal, Poseida will become a wholly owned subsidiary of Swiss pharmaceutical giant Roche. Josh Abbott, Editor, BioProcess InsiderRoche Holding AG is acquiring clinical-stage cell and gene therapy (CGT) developer Poseida Therapeutics in the finalization of a $1.5 billion deal first announced in December 2024.
-
Jan 8, 2025 | 
bioprocessintl.com | Josh Abbott
“In the US, fewer than 5% of hospitals have the experience and capabilities needed to manage and administer advanced cellular therapies,” said Jeff Wren, VP of biotherapies for Association for the Advancement of Blood & Biotherapies (AABB).
-
Jan 7, 2025 | 
bioprocessintl.com | Josh Abbott
In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year manufacturing and distributing vaccines for COVID-19, admitting that sales in the US have declined due to increased market competition while global sales have had a mixed performance. To counter such issues, the company is looking to decrease research and development (R&D) expenditures and drive efficient manufacturing.
-
Dec 9, 2024 | 
bioprocessintl.com | Josh Abbott
Passage of the BIOSECURE Act has been delayed after being excluded from the end-of-year defense spending bill that the US government unveiled over the weekend. If passed into law, the BIOSECURE Act would restrict certain named Chinese companies from doing business with and receiving funding from the US government. Contract development and manufacturing organization (CDMO) WuXi Biologics and biopharmaceutical and medical device company WuXi Apptec are among those companies named in the Act.
-
Dec 9, 2024 | 
bioprocessintl.com | Josh Abbott
In November, contract development and manufacturing organization (CDMO) Lonza announced the expansion of its bioconjugation facilities in Visp, Switzerland, wherein the firm pledged to add 200 jobs to two multipurpose suites by 2028.
-
Dec 5, 2024 | 
bioprocessintl.com | Josh Abbott
Eli Lilly and Company announced a $3 billion expansion to its injectable product manufacturing site. The facility produces glucagon-like peptide-1 (GLP-1) drug products, which are used to treat diabetes and obesity. The site also has fill-finish capabilities. “Obesity is especially pervasive across our country as rates continue to rise here in the US and around the world,” said David Ricks, CEO of chair of Lilly during a live presentation in Kenosha County.
-
Dec 5, 2024 | 
bioprocessintl.com | Josh Abbott
Biotechnology company Amgen is building a $1 billion drug substance manufacturing facility in Holly Springs, North Carolina, expanding its presence in the region with its second such facility. In tandem with its other investments, Amgen’s presence will add about 370 jobs to Wake County, providing full-time roles for technicians, engineers, management, and administration. Holly Springs is part of the research triangle region which houses many of the world’s largest biotechnology companies.
